Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

109.84
-0.9500-0.86%
Post-market: 109.67-0.1700-0.15%17:11 EDT
Volume:2.49M
Turnover:272.59M
Market Cap:12.47B
PE:32.48
High:110.64
Open:109.41
Low:107.41
Close:110.79
52wk High:116.85
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:1.16
T/O Rate:2.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:86.85
PE(LYR):42.91

Loading ...

Halozyme Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $130 from $115

THOMSON REUTERS
·
Yesterday

US Research Roundup-BlackRock, Evercore, Goldman Sachs

Reuters
·
Yesterday

Does Patent Injunction Win Change The Bull Case For Halozyme Therapeutics (HALO)?

Simply Wall St.
·
Yesterday

US Stocks on the MOVE-Halozyme, Moderna, Merck

Reuters
·
Yesterday

Sector Update: Healthcare

MT Newswires Live
·
Yesterday

Merck's Keytruda is Dealt a Legal Setback. It's Good News for This Biotech Stock.

Dow Jones
·
Yesterday

U.S. Stocks on the MOVE-Halozyme, BKV, AppFolio

Reuters
·
Yesterday

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Oct 07

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Oct 07

Halozyme Wins Dutch Court Injunction Blocking Merck Keytruda SC in Eight European Markets over EP622 Patent

Reuters
·
Oct 07

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Oct 07

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda Sc in Multiple European Markets

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Orders Msd BV to Stop Keytruda Sc Manufacture and Sale in Eight European Countries

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Injunction Forbids Msd from Facilitating Infringement by Affiliates

THOMSON REUTERS
·
Oct 07

Halozyme Expands Enhanze Collaboration with Argenx to Cover Two Additional Exclusive Targets

Reuters
·
Oct 07

Halozyme Therapeutics - Eligible for Milestone Payments and Royalties on Enhanze Product Sales

THOMSON REUTERS
·
Oct 07

Halozyme Announces Expansion of Global Collaboration and License Agreement with Argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using Its Enhanze® Technology

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Increases Argenx's Exclusive Access to Enhanze Increased from Six to Eight Targets

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics (HALO) Adds Jim Daly As Valuation Questions Follow

Simply Wall St.
·
Oct 04